info@bivictrix.com
January 31st, 2023
BiVictriX announces positive data from preclinical study of BVX001
Read more
January 06th, 2023
BiVictriX Therapeutics announces Board Change
Read more
December 07th, 2022
BiVictriX identifies development lead for BVX001 programme
Read more
September 12th, 2022
BiVictriX Interim results for the six months ended 30 June 2022
Read more
July 11th, 2022
BiVictriX Therapeutics Pipeline update 2022
Read more
May 23rd, 2022
BiVictriX to present at the Immuno-Oncology Summit Europe 2022
Read more
April 05th, 2022
BiVictriX receives Bionow Investment Deal of the Year Award
Read more
March 31st, 2022
Results of Annual General Meeting
Read more
March 09th, 2022
Publication of Annual Report and Notice of AGM
Read more
March 07th, 2022
Maiden full year results for the twelve months ended 31 December 2021
Read more
February 23rd, 2022
BiVictriX announces expansion of its therapeutic pipeline with two additional drug discovery programmes
Read more
February 22nd, 2022
BiVictriX Strengthens Its Patent Portfolio
Read more
Load more
Quick links
Head office
Mereside
Alderley Park
Alderley Edge
Cheshire, UK
SK10 4TG info@bivictrix.com
Copyright: BiVictriX Therapeutics plc 2023.

All Rights Reserved. Design & Development By CLICK